Clinical assessment of the cancer diagnostic value of prostatic zinc: A comprehensive needle‐biopsy study

Cortesi, M.; Fridman, Eduard; Volkov, Alexander; Shilstein, S.Sh.; Chechik, R.; Breskin, A.; Vartsky, D.; Kleinman, Nathan L.; Kogan, Grigorij; Moriel, Evyatar Z.; Gladysh, V.; Huszar, Monica; Ramon, Jacob; Raviv, Gil

doi:10.1002/pros.20766

Cited by 43 publications

(35 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of importance is the demonstration that this concurrent loss of ZIP1, zinc, and citrate occurs in premalignant and early stage development of malignancy and persists in the progression of malignancy. 10,[17][18][19] Since the cellular zinc level that exists in the highly specialized normal peripheral zone glandular epithelial cells is cytotoxic in the malignant cells, the silencing of ZIP1 gene expression results in loss of cellular zinc accumulation, which eliminates the adverse effects on malignancy.…”

Section: Discussionmentioning

confidence: 99%

Human prostate cancer ZIP1/zinc/citrate genetic/metabolic relationship in the TRAMP prostate cancer animal model

Costello

Franklin

Zou

et al. 2011

Cancer Biology & Therapy

View full text Add to dashboard Cite

Prostate cancer is the second leading cause of cancer deaths among men. The availability of animal models that represent the events and factors that exist in the natural history and biology of human prostate cancer is essential in dealing with prostate cancer. In recent decades and presently, emphasis has been directed at the development and employment of prostate cancer induced in transgenic mice. However, the important consistent hallmark characteristic and event of decrease in zinc and citrate and downregulation of ZIP1 zinc transporter in prostate malignancy has not been studied or identified in any animal model. We investigated the status of these parameters in TRAMP tumors as compared with human prostate cancer. The results show that citrate levels are markedly decreased in the developing and advancing stages of malignancy in TRAMP. Zinc levels are also decreased and ZIP1 transporter is lost in TRAMP tumors. In vitro studies show that zinc treatment of TRAMP C2 cells exhibits cytotoxic effects. Collectively, these results mimic the ZIP1, zinc, and citrate status and relationship that exist in human prostate cancer. This is the first report that establishes the existence of the human prostate zinc/citrate hallmark characteristic and relationship in an animal model. It now appears that the TRAMP model will be suitable for studies relating to the implications and role of zinc-and citraterelated metabolism in the development and progression of human prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Human prostate cancer ZIP1/zinc/citrate genetic/metabolic relationship in the TRAMP prostate cancer animal model

Costello

Franklin

Zou

et al. 2011

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…Such a relationship exists for zinc and ZIP1 in prostate cancer. [32][33][34] These are potential biomarkers for the early developing premalignant stages of pancreatic carcinogenesis.…”

Section: Methodsmentioning

confidence: 99%

Decreased zinc and downregulation of ZIP3 zinc uptake transporter in the development of pancreatic adenocarcinoma

Costello

Levy

Desouki

et al. 2011

Cancer Biology & Therapy

View full text Add to dashboard Cite

“…In cell culture systems, zinc has been shown to inhibit prostate cancer cell growth via inhibition of cell cycle and induction of apoptosis through disruption of mitochondrial function (Liang et al 1999b). Comprehensive prostate needle-biopsy study suggested that the amount of zinc depletion could be used as a measure of the Gleason score of the tumor (Cortesi et al 2008). Local zinc concentration mapping has the potential to improve patient selection for biopsy, biopsy site selection and local therapy such as cryotherapy and brachytherapy (Cortesi et al 2008).…”

Section: Mineralsmentioning

confidence: 99%

“…Comprehensive prostate needle-biopsy study suggested that the amount of zinc depletion could be used as a measure of the Gleason score of the tumor (Cortesi et al 2008). Local zinc concentration mapping has the potential to improve patient selection for biopsy, biopsy site selection and local therapy such as cryotherapy and brachytherapy (Cortesi et al 2008).…”

Section: Mineralsmentioning

confidence: 99%

Current Status and Future Prospects of Nutraceuticals in Prostate Cancer

Shukla

Gupta

2011

Nutraceuticals and Cancer

View full text Add to dashboard Cite

Nutraceuticals are products derived from food sources that provide health benefits. Several natural dietary agents have been studied for their preventive and/or therapeutic effects against prostate cancer. Although most of the information on nutraceuticals and prostate cancer is drawn from epidemiologic and case-control studies, clinical studies conducted so far have not provided clear-cut results. The lack of evidence-based studies limits the use of nutraceuticals and their clinical recommendations. In spite these limitations, the field of nutraceutical research continues to emerge as many of these nutritional agents are tested for their therapeutic potential in pre-clinical and clinical settings. Nutraceuticals have the potential for significant medical and economic impacts. This chapter highlights the present status of nutraceuticals in prostate cancer and discusses future prospects for nutritional strategies that are safe and clinically beneficial.

show abstract

Clinical assessment of the cancer diagnostic value of prostatic zinc: A comprehensive needle‐biopsy study

Cited by 43 publications

References 15 publications

Human prostate cancer ZIP1/zinc/citrate genetic/metabolic relationship in the TRAMP prostate cancer animal model

Human prostate cancer ZIP1/zinc/citrate genetic/metabolic relationship in the TRAMP prostate cancer animal model

Decreased zinc and downregulation of ZIP3 zinc uptake transporter in the development of pancreatic adenocarcinoma

Current Status and Future Prospects of Nutraceuticals in Prostate Cancer

Contact Info

Product

Resources

About